Fibulin 1 and 2 Levels in Patients with Heart Failure: Comparison of Different Heart Failure Stages and Exploring the Temporal Changes During Acute Exacerbation
Background: Fibulin 1 and Fibulin 2 are members of the extracellular matrix (ECM) glycoprotein family. ECMs drive prognosis through remodeling, a key step in the pathogenesis of heart failure (HF). We aimed to compare Fibulin 1 and 2 levels in different stages of HF and to investi...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
IMR Press
2025-02-01
|
| Series: | Reviews in Cardiovascular Medicine |
| Subjects: | |
| Online Access: | https://www.imrpress.com/journal/RCM/26/2/10.31083/RCM26364 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850204826408845312 |
|---|---|
| author | Burcu Cihan Talay Emrullah Kızıltunç Canan Yılmaz Zakir Osmanov Serkan Ünlü Mustafa Candemir Burak Sezenöz Özden Seçkin Göbüt Salih Topal Sedat Türkoğlu |
| author_facet | Burcu Cihan Talay Emrullah Kızıltunç Canan Yılmaz Zakir Osmanov Serkan Ünlü Mustafa Candemir Burak Sezenöz Özden Seçkin Göbüt Salih Topal Sedat Türkoğlu |
| author_sort | Burcu Cihan Talay |
| collection | DOAJ |
| description | Background: Fibulin 1 and Fibulin 2 are members of the extracellular matrix (ECM) glycoprotein family. ECMs drive prognosis through remodeling, a key step in the pathogenesis of heart failure (HF). We aimed to compare Fibulin 1 and 2 levels in different stages of HF and to investigate their relationship with other prognostic factors of HF. Methods: Patients with HF were divided into two groups according to left ventricular ejection fraction (LVEF): reduced and non-reduced LVEF. The control and patient groups consisted of individuals with Stages A and B HF, Stages C and D HF, respectively. Fibulin levels were measured at different stages of HF and in the control group. Additionally, Fibulin levels were measured at admission, discharge, and in the first month in patients who were hospitalized due to decompensated HF. Results: Serum Fibulin 1 and N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels were significantly higher in the patient group than in the control group. Serum Fibulin 2 levels were similar between the groups. Although serum Fibulin 2 levels were similar at repeated measurements, serum Fibulin 1 and NT-proBNP levels significantly decreased at discharge and remained similar at 1 month compared with admission. There was a significant positive correlation between Fibulin 1 and NT-proBNP levels and a significant negative correlation between Fibulin 1 levels and LVEF. Fibulin 2 levels were not correlated with LVEF and NT-proBNP. Conclusions: Our study demonstrated that serum Fibulin 1 levels differ among different HF stages and have a similar temporal change as observed for NT-proBNP levels. A similar association was not observed for Fibulin 2 in our study. |
| format | Article |
| id | doaj-art-ef1151cd64524a7fb4d672ddc8d37841 |
| institution | OA Journals |
| issn | 1530-6550 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | IMR Press |
| record_format | Article |
| series | Reviews in Cardiovascular Medicine |
| spelling | doaj-art-ef1151cd64524a7fb4d672ddc8d378412025-08-20T02:11:13ZengIMR PressReviews in Cardiovascular Medicine1530-65502025-02-012622636410.31083/RCM26364S1530-6550(24)01669-7Fibulin 1 and 2 Levels in Patients with Heart Failure: Comparison of Different Heart Failure Stages and Exploring the Temporal Changes During Acute ExacerbationBurcu Cihan Talay0Emrullah Kızıltunç1Canan Yılmaz2Zakir Osmanov3Serkan Ünlü4Mustafa Candemir5Burak Sezenöz6Özden Seçkin Göbüt7Salih Topal8Sedat Türkoğlu9Department of Cardiology, Bilecik Bozüyük State Hospital, 11300 Bilecik, TurkeyDepartment of Cardiology, Gazi University School of Medicine, 06560 Ankara, TurkeyDepartment of Medical Biochemistry, Gazi University School of Medicine, 06560 Ankara, TurkeyDepartment of Medical Biochemistry, Gazi University School of Medicine, 06560 Ankara, TurkeyDepartment of Cardiology, Gazi University School of Medicine, 06560 Ankara, TurkeyDepartment of Cardiology, Gazi University School of Medicine, 06560 Ankara, TurkeyDepartment of Cardiology, Gazi University School of Medicine, 06560 Ankara, TurkeyDepartment of Cardiology, Gazi University School of Medicine, 06560 Ankara, TurkeyDepartment of Cardiology, Gazi University School of Medicine, 06560 Ankara, TurkeyDepartment of Cardiology, Gazi University School of Medicine, 06560 Ankara, TurkeyBackground: Fibulin 1 and Fibulin 2 are members of the extracellular matrix (ECM) glycoprotein family. ECMs drive prognosis through remodeling, a key step in the pathogenesis of heart failure (HF). We aimed to compare Fibulin 1 and 2 levels in different stages of HF and to investigate their relationship with other prognostic factors of HF. Methods: Patients with HF were divided into two groups according to left ventricular ejection fraction (LVEF): reduced and non-reduced LVEF. The control and patient groups consisted of individuals with Stages A and B HF, Stages C and D HF, respectively. Fibulin levels were measured at different stages of HF and in the control group. Additionally, Fibulin levels were measured at admission, discharge, and in the first month in patients who were hospitalized due to decompensated HF. Results: Serum Fibulin 1 and N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels were significantly higher in the patient group than in the control group. Serum Fibulin 2 levels were similar between the groups. Although serum Fibulin 2 levels were similar at repeated measurements, serum Fibulin 1 and NT-proBNP levels significantly decreased at discharge and remained similar at 1 month compared with admission. There was a significant positive correlation between Fibulin 1 and NT-proBNP levels and a significant negative correlation between Fibulin 1 levels and LVEF. Fibulin 2 levels were not correlated with LVEF and NT-proBNP. Conclusions: Our study demonstrated that serum Fibulin 1 levels differ among different HF stages and have a similar temporal change as observed for NT-proBNP levels. A similar association was not observed for Fibulin 2 in our study.https://www.imrpress.com/journal/RCM/26/2/10.31083/RCM26364heart failurefibulin-1fibulin-2extracellular matrix |
| spellingShingle | Burcu Cihan Talay Emrullah Kızıltunç Canan Yılmaz Zakir Osmanov Serkan Ünlü Mustafa Candemir Burak Sezenöz Özden Seçkin Göbüt Salih Topal Sedat Türkoğlu Fibulin 1 and 2 Levels in Patients with Heart Failure: Comparison of Different Heart Failure Stages and Exploring the Temporal Changes During Acute Exacerbation Reviews in Cardiovascular Medicine heart failure fibulin-1 fibulin-2 extracellular matrix |
| title | Fibulin 1 and 2 Levels in Patients with Heart Failure: Comparison of Different Heart Failure Stages and Exploring the Temporal Changes During Acute Exacerbation |
| title_full | Fibulin 1 and 2 Levels in Patients with Heart Failure: Comparison of Different Heart Failure Stages and Exploring the Temporal Changes During Acute Exacerbation |
| title_fullStr | Fibulin 1 and 2 Levels in Patients with Heart Failure: Comparison of Different Heart Failure Stages and Exploring the Temporal Changes During Acute Exacerbation |
| title_full_unstemmed | Fibulin 1 and 2 Levels in Patients with Heart Failure: Comparison of Different Heart Failure Stages and Exploring the Temporal Changes During Acute Exacerbation |
| title_short | Fibulin 1 and 2 Levels in Patients with Heart Failure: Comparison of Different Heart Failure Stages and Exploring the Temporal Changes During Acute Exacerbation |
| title_sort | fibulin 1 and 2 levels in patients with heart failure comparison of different heart failure stages and exploring the temporal changes during acute exacerbation |
| topic | heart failure fibulin-1 fibulin-2 extracellular matrix |
| url | https://www.imrpress.com/journal/RCM/26/2/10.31083/RCM26364 |
| work_keys_str_mv | AT burcucihantalay fibulin1and2levelsinpatientswithheartfailurecomparisonofdifferentheartfailurestagesandexploringthetemporalchangesduringacuteexacerbation AT emrullahkızıltunc fibulin1and2levelsinpatientswithheartfailurecomparisonofdifferentheartfailurestagesandexploringthetemporalchangesduringacuteexacerbation AT cananyılmaz fibulin1and2levelsinpatientswithheartfailurecomparisonofdifferentheartfailurestagesandexploringthetemporalchangesduringacuteexacerbation AT zakirosmanov fibulin1and2levelsinpatientswithheartfailurecomparisonofdifferentheartfailurestagesandexploringthetemporalchangesduringacuteexacerbation AT serkanunlu fibulin1and2levelsinpatientswithheartfailurecomparisonofdifferentheartfailurestagesandexploringthetemporalchangesduringacuteexacerbation AT mustafacandemir fibulin1and2levelsinpatientswithheartfailurecomparisonofdifferentheartfailurestagesandexploringthetemporalchangesduringacuteexacerbation AT buraksezenoz fibulin1and2levelsinpatientswithheartfailurecomparisonofdifferentheartfailurestagesandexploringthetemporalchangesduringacuteexacerbation AT ozdenseckingobut fibulin1and2levelsinpatientswithheartfailurecomparisonofdifferentheartfailurestagesandexploringthetemporalchangesduringacuteexacerbation AT salihtopal fibulin1and2levelsinpatientswithheartfailurecomparisonofdifferentheartfailurestagesandexploringthetemporalchangesduringacuteexacerbation AT sedatturkoglu fibulin1and2levelsinpatientswithheartfailurecomparisonofdifferentheartfailurestagesandexploringthetemporalchangesduringacuteexacerbation |